Targeting the Transforming Growth Factor-beta Signaling Pathway in Human Cancer

Overview

Journal Expert Opin Investig Drugs

Specialty Pharmacology

Date 2009 Dec 17

PMID 20001556

Citations 131

Authors

Nagathihalli S Nagaraj

Pran K Datta

Affiliations

Soon will be listed here.

Abstract

The transforming growth factor-ss (TGF-beta) signaling pathway plays a pivotal role in diverse cellular processes. TGF-beta switches its role from a tumor suppressor in normal or dysplastic cells to a tumor promoter in advanced cancers. It is widely believed that the Smad-dependent pathway is involved in TGF-beta tumor-suppressive functions, whereas activation of Smad-independent pathways, coupled with the loss of tumor-suppressor functions of TGF-beta, is important for its pro-oncogenic functions. TGF-beta signaling has been considered a useful therapeutic target. The discovery of oncogenic actions of TGF-beta has generated a great deal of enthusiasm for developing TGF-beta signaling inhibitors for the treatment of cancer. The challenge is to identify the group of patients where targeted tumors are not only refractory to TGF-beta-induced tumor suppressor functions but also responsive to the tumor-promoting effects of TGF-beta. TGF-beta pathway inhibitors, including small and large molecules, have now entered clinical trials. Preclinical studies with these inhibitors have shown promise in a variety of different tumor models. Here, we focus on the mechanisms of signaling and specific targets of the TGF-beta pathway that are critical effectors of tumor progression and invasion. This report also examines the therapeutic intervention of TGF-ss signaling in human cancers.

Citing Articles

MicroRNA155 in non-small cell lung cancer: a potential therapeutic target.

Wei X, Xiong X, Chen Z, Chen B, Zhang C, Zhang W Front Oncol. 2025; 15:1517995.

PMID: 39963112 PMC: 11830606. DOI: 10.3389/fonc.2025.1517995.

A new method for network bioinformatics identifies novel drug targets for mucinous ovarian carcinoma.

Craig O, Lee S, Pilcher C, Saoud R, Abdirahman S, Salazar C NAR Genom Bioinform. 2024; 6(3):lqae096.

PMID: 39184376 PMC: 11344246. DOI: 10.1093/nargab/lqae096.

Fibrostenosing Crohn's Disease: Pathogenetic Mechanisms and New Therapeutic Horizons.

Mignini I, Blasi V, Termite F, Esposto G, Borriello R, Laterza L Int J Mol Sci. 2024; 25(12).

PMID: 38928032 PMC: 11204249. DOI: 10.3390/ijms25126326.

Expanding the Chemical Space of Transforming Growth Factor-β (TGFβ) Receptor Type II Degraders with 3,4-Disubstituted Indole Derivatives.

Langle D, Wojtowicz-Piotrowski S, Priegann T, Keller N, Wesseler F, Reckzeh E ACS Pharmacol Transl Sci. 2024; 7(4):1069-1085.

PMID: 38633593 PMC: 11020067. DOI: 10.1021/acsptsci.3c00371.

Hydrogel-based cardiac repair and regeneration function in the treatment of myocardial infarction.

Xu Q, Xiao Z, Yang Q, Yu T, Deng X, Chen N Mater Today Bio. 2024; 25:100978.

PMID: 38434571 PMC: 10907859. DOI: 10.1016/j.mtbio.2024.100978.

References

Bandyopadhyay A, Zhu Y, Malik S, Kreisberg J, Brattain M, Sprague E . Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene. 2002; 21(22):3541-51. DOI: 10.1038/sj.onc.1205439. View

Law B, Chytil A, Dumont N, Hamilton E, Aakre M, Covington C . Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol Cell Biol. 2002; 22(23):8184-98. PMC: 134072. DOI: 10.1128/MCB.22.23.8184-8198.2002. View

Myeroff L, Parsons R, Kim S, Hedrick L, Cho K, Orth K . A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res. 1995; 55(23):5545-7. View

Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, Goto K . Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci. 2006; 98(1):127-33. PMC: 11159712. DOI: 10.1111/j.1349-7006.2006.00357.x. View

Davis B, Hilyard A, Lagna G, Hata A . SMAD proteins control DROSHA-mediated microRNA maturation. Nature. 2008; 454(7200):56-61. PMC: 2653422. DOI: 10.1038/nature07086. View

Annes J, Munger J, Rifkin D . Making sense of latent TGFbeta activation. J Cell Sci. 2002; 116(Pt 2):217-24. DOI: 10.1242/jcs.00229. View

Gatto B . Monoclonal antibodies in cancer therapy. Curr Med Chem Anticancer Agents. 2004; 4(5):411-4. DOI: 10.2174/1568011043352713. View

Datta P, Moses H . STRAP and Smad7 synergize in the inhibition of transforming growth factor beta signaling. Mol Cell Biol. 2000; 20(9):3157-67. PMC: 85610. DOI: 10.1128/MCB.20.9.3157-3167.2000. View

Chen C, Kang Y, Massague J . Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci U S A. 2001; 98(3):992-9. PMC: 14697. DOI: 10.1073/pnas.98.3.992. View

10.

Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A . Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides. 2007; 17(2):201-12. DOI: 10.1089/oli.2006.0053. View

11.

Guasch G, Schober M, Pasolli H, Conn E, Polak L, Fuchs E . Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. Cancer Cell. 2007; 12(4):313-27. PMC: 2424201. DOI: 10.1016/j.ccr.2007.08.020. View

12.

Derynck R, Zhang Y . Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425(6958):577-84. DOI: 10.1038/nature02006. View

13.

Hjelmeland M, Hjelmeland A, Sathornsumetee S, Reese E, Herbstreith M, Laping N . SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther. 2004; 3(6):737-45. View

14.

Oft M, Akhurst R, Balmain A . Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol. 2002; 4(7):487-94. DOI: 10.1038/ncb807. View

15.

Tanaka Y, Kobayashi H, Suzuki M, Kanayama N, Terao T . Transforming growth factor-beta1-dependent urokinase up-regulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells. J Biol Chem. 2003; 279(10):8567-76. DOI: 10.1074/jbc.M309131200. View

16.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

17.

Ten Dijke P, Arthur H . Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol. 2007; 8(11):857-69. DOI: 10.1038/nrm2262. View

18.

Nemunaitis J, Jahan T, Ross H, Sterman D, Richards D, Fox B . Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther. 2006; 13(6):555-62. DOI: 10.1038/sj.cgt.7700922. View

19.

Kretzschmar M, Doody J, Timokhina I, Massague J . A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes Dev. 1999; 13(7):804-16. PMC: 316599. DOI: 10.1101/gad.13.7.804. View

20.

Massague J, Seoane J, Wotton D . Smad transcription factors. Genes Dev. 2005; 19(23):2783-810. DOI: 10.1101/gad.1350705. View